0 CHECKOUT

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015

  • ID: 3308771
  • June 2015
  • 94 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advinus Therapeutics Ltd.
  • iCo Therapeutics Inc.
  • Merck KGaA
  • Mologen AG
  • Nanomerics Ltd
  • Sanofi
  • MORE

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015

Summary

This, ‘Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015’, provides an overview of the Leishmaniasis (Kala-Azar)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advinus Therapeutics Ltd.
  • iCo Therapeutics Inc.
  • Merck KGaA
  • Mologen AG
  • Nanomerics Ltd
  • Sanofi
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Leishmaniasis (Kala-Azar) Overview
Therapeutics Development
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes
Leishmaniasis (Kala-Azar) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Leishmaniasis (Kala-Azar) - Products under Development by Companies
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development
Advinus Therapeutics Ltd.
Anacor Pharmaceuticals, Inc.
Dafra Pharma International Ltd.
Georgia Tech Research Corporation
iCo Therapeutics Inc.
Merck KGaA
Mologen AG
Nanomerics Ltd
Sanofi
Takeda Pharmaceutical Company Limited
Zydus Cadila Healthcare Limited
Leishmaniasis (Kala-Azar) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amphotericin b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amphotericin b NanoDisk - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-605240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CDRI-99/288 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
corifungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fexinidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Indotecan hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KVH-14 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methoxycoronaridine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-1331 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPC-1161B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oleylphosphocholine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegylated amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-010269 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Visceral Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Infectious Disease and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Protozoal Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Visceral Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGP-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
visceral leishmaniasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VL-2098 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leishmaniasis (Kala-Azar) - Recent Pipeline Updates
Leishmaniasis (Kala-Azar) - Dormant Projects
Leishmaniasis (Kala-Azar) - Discontinued Products
Leishmaniasis (Kala-Azar) - Product Development Milestones
Featured News & Press Releases
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions
Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients
Mar 19, 2014: Knight Therapeutics Announces FDA Approval for Impavido (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis
Nov 11, 2013: Paladin Announces Extension of the Impavido® PDUFA Date by Three Months
Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis
Dec 17, 2012: PATH’s Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh
Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis
Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2015
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Dafra Pharma International Ltd., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Georgia Tech Research Corporation, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Merck KGaA, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Sanofi, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Leishmaniasis (Kala-Azar) - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Leishmaniasis (Kala-Azar) Therapeutics - Recent Pipeline Updates, H1 2015
Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2015
Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2015
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Advinus Therapeutics Ltd.
Anacor Pharmaceuticals, Inc.
Dafra Pharma International Ltd.
Georgia Tech Research Corporation
iCo Therapeutics Inc.
Merck KGaA
Mologen AG
Nanomerics Ltd
Sanofi
Takeda Pharmaceutical Company Limited
Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.